About Mercy BioAnalytics
Mercy BioAnalytics is a company based in Boston (United States) founded in 2018 by Paul Blavin and Joseph Sedlak.. Mercy BioAnalytics has raised $127.28 million across 3 funding rounds from investors including LabCorp, Hologic and Bruker. The company has 18 employees as of December 31, 2021. Mercy BioAnalytics offers products and services including Mercy Halo Platform and Blood-based Tests.
- Headquarter Boston, United States
- Employees 18 as on 31 Dec, 2021
- Founders Paul Blavin, Joseph Sedlak
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Mercy Bioanalytics, Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$127.28 M (USD)
in 3 rounds
-
Latest Funding Round
$59 M (USD), Series B
Sep 03, 2025
-
Investors
LabCorp
& 14 more
-
Employee Count
18
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Mercy BioAnalytics
Mercy BioAnalytics offers a comprehensive portfolio of products and services, including Mercy Halo Platform and Blood-based Tests. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
The Mercy Halo platform is used for developing blood-based tests that identify early-stage cancer through extracellular vesicles
Blood-based tests are developed for detecting cancer at early stages using biomarker analysis on extracellular vesicles
Unlock access to complete
Funding Insights of Mercy BioAnalytics
Mercy BioAnalytics has successfully raised a total of $127.28M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $59 million completed in September 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series B — $59.0M
-
First Round
First Round
(29 Jan 2021)
- Investors Count 15
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2025 | Amount | Series B - Mercy BioAnalytics | Valuation | Novalis LifeSciences , Sozo Ventures | |
| Apr, 2023 | Amount | Series A - Mercy BioAnalytics | Valuation | Novalis LifeSciences | |
| Jan, 2021 | Amount | Series A - Mercy BioAnalytics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Mercy BioAnalytics
Mercy BioAnalytics has secured backing from 15 investors, including venture fund and institutional investors. Prominent investors backing the company include LabCorp, Hologic and Bruker. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment and advisory services are provided for life sciences.
|
Founded Year | Domain | Location | |
|
Tech & Life Sciences focused VC firm investing in early stage companies in the US & Europe
|
Founded Year | Domain | Location | |
|
Early-stage investments are targeted by iSelect Fund in key sectors.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Mercy BioAnalytics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Mercy BioAnalytics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Mercy Bioanalytics Comparisons
Competitors of Mercy BioAnalytics
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Mercy BioAnalytics
When was Mercy BioAnalytics founded?
Mercy BioAnalytics was founded in 2018 and raised its 1st funding round 3 years after it was founded.
Where is Mercy BioAnalytics located?
Mercy BioAnalytics is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Who is the current CEO of Mercy BioAnalytics?
Paul Blavin is the current CEO of Mercy BioAnalytics. They have also founded this company.
Is Mercy BioAnalytics a funded company?
Mercy BioAnalytics is a funded company, having raised a total of $127.28M across 3 funding rounds to date. The company's 1st funding round was a Series A of $27.28M, raised on Jan 29, 2021.
How many employees does Mercy BioAnalytics have?
As of Dec 31, 2021, the latest employee count at Mercy BioAnalytics is 18.
What does Mercy BioAnalytics do?
Mercy BioAnalytics was founded in 2018 and is based in Boston, United States. Diagnostic test devices are produced by the company within the biotechnology sector. Operations focus on developing and manufacturing these devices to support healthcare diagnostics. The firm is led by co-founders Paul Blavin as CEO and Joseph Sedlak as CSO. Activities are conducted through the domain mercybio.com, serving the medical industry in the region.
What products or services does Mercy BioAnalytics offer?
Mercy BioAnalytics offers Mercy Halo Platform and Blood-based Tests.
Who are Mercy BioAnalytics's investors?
Mercy BioAnalytics has 15 investors. Key investors include LabCorp, Hologic, Bruker, Novalis LifeSciences, and SOZO Ventures.